Registration and Breakfast

Session Starts
Nobel Prize Winner – Professor Sydney Brenner

Private Finance/Public Markets

Is the only real exit an M&A or Trade Sale?

In a market that values both late stage products and fiscally responsible management, spin outs appear to offer a win-win solution, experienced teams and often products in the clinic. Or they may build de novo sale and pipeline through early marketing of niche products and formation of formulation/development relationships. An alternative approach is seen with the growth in semi-virtual companies where experienced biotech and pharma individuals get together to acquire and manage product development through the clinic. However, for companies to develop they must reflect and adapt to investor requirements and appetites, in an ever changing funding environment. The panel will reflect on the successes of different models and on what is now the funding model for a successful biotech company, in what is fast becoming a globally competitive funding environment.

Chairing the session:
Mr Toby Wilson Waterworth,Dealmaker, Healthcare and Life Sciences, Global Entrepreneur Programme, British Government

• Dr Barry Kenny, VP Drug Discovery, Takeda Cambridge Ltd
• Dr Muneo Takatani, General Manager, Global Research Management, Takeda Pharmaceutical Company, Japan
• Mr Tim Sharpington, CEO, Serentis Ltd
• Mr Allan Cambridge, CEO, Atlantic Healthcare Ltd
• Dr Francesca Crawford, CEO, Altacor

Morning Break

The Way Ahead

A look at the new UK Life Sciences Strategy

Miss Harriet Fear, UK Trade & Investment

Treating Cancer in the 21st Century

Cancer is fast becoming one of the world’s biggest killers and research is the key to increasing our understanding of this disease. We hear from leading companies and a patient group to learn what is happening and needed to lead to ever-more effective treatments and methods for early detection.

Chairing the session:
Professor Barry Furr, Consultant Chief Scientist, AstraZeneca

• Professor Karol Sikora, Medical Director, CancerPartnersUK
• Professor Tim Eden, TCT Professor of Teenage and Young Adult Cancer, Teenage Cancer Trust
• Dr David Tuveson, Senior Group Leader, University of Cambridge - Tumour Modelling and Cancer Medicine Laboratory
• Dr Harren Jhoti, CEO, Astex Therapeutics
• Professor Conrad Lichtenstein, COO, Population Genetics Technologies Ltd 

Lunch

Getting old in the 21st Century

Will Ageing and Neural Diseases Disappear?

Most of us understand that Europe is turning grey; that more and more of us will soon join legions of the elderly. Pre-eminent amongst ageing-related diseases is Alzheimer’s dementia that currently affects approximately 1% of the world’s population. Its incidence increases in the elderly, particularly past the age of 65 (late onset AD) where the chance of developing the disease is about 3% and doubles every five years. We hear from the leading experts who research changes that accumulate with age and reduce remaining life expectancy, and talk about how radical therapies can be developed in the post-VC era.

• Dr Russell Hagan, Head of R&D, BTG plc
• Dr Mark Treherne, CEO, Senexis Ltd
• Professor William Bains, CEO, Delta G Ltd
• Dr Aubrey De Grey, Chairman & CSO, Methuselah Foundation

Student Presentations

• Speaker from AutoTB
• Speaker from Rescent
• Speaker from Temperature Concepts

Drinks Reception in the Orchard